Daily Cosmetic Research Analysis
Analyzed 2 papers and selected 2 impactful papers.
Summary
The two provided papers highlight contrasting advances in cosmetic-related research: one identifies substantial methodological barriers preventing clinical implementation of artificial intelligence and machine learning risk models in plastic surgery, while the other demonstrates renewable microbial production of isoprene glycol from glucose. Only two papers were provided, so a scientifically valid third paper could not be selected without fabricating information.
Research Themes
- Artificial intelligence and machine learning validation in plastic surgery
- Methodological quality and clinical readiness of prediction models
- Sustainable microbial biomanufacturing for cosmetic ingredients
Selected Articles
1. Methodological quality and performance of artificial intelligence and machine learning models for preoperative risk prediction in plastic surgery: A systematic review.
This systematic review evaluated 10 preoperative AI/ML risk-prediction studies in plastic surgery using the PROBAST+AI framework. Discrimination was variable, with AUC values of 0.66–0.82, and important limitations included external validation in only 2 studies, inadequate events per variable in 5 of 7 development studies, and absent calibration reporting in 7 studies.
Impact: The paper provides a structured, field-specific assessment showing that apparently promising AI/ML models should not yet be adopted clinically without prospective, multi-institutional validation. Its negative findings directly inform safe implementation and research standards.
Clinical Implications: Clinicians and health systems should avoid using these models for routine preoperative decision-making until external validation, adequate sample sizes, calibration assessment, and prospective evaluation are available. The review supports requiring transparent reporting and robust validation before AI-assisted risk stratification is incorporated into plastic-surgery pathways.
Key Findings
- Ten studies were included across breast reconstruction, head and neck reconstruction, burn surgery, and aesthetic surgery.
- Among 8 studies reporting discrimination, AUC values ranged from 0.66 to 0.82.
- Only 2 of 10 studies performed external validation, 5 of 7 development studies had fewer than 10 events per variable, and 7 of 10 did not report calibration.
Methodological Strengths
- The review searched five databases through October 2025 and applied the PROBAST+AI framework to assess quality, bias, and predictive performance.
- Disagreements in 102 paired domain-level ratings were resolved through structured consensus, improving consistency of the final assessments.
Limitations
- The evidence base consisted of only 10 studies, limiting the precision and generalizability of conclusions.
- The review identified substantial deficiencies in the primary studies, including limited external validation, inadequate sample sizes, and incomplete calibration reporting.
Future Directions: Future studies should use multi-institutional prospective cohorts, prespecified development and validation protocols, adequate event-per-variable ratios, calibration assessment, transparent reporting, and independent external validation. Clinical impact should ultimately be tested in implementation or pragmatic studies rather than inferred from discrimination alone.
Artificial intelligence (AI) and machine learning (ML) are increasingly being applied to preoperative risk prediction in plastic surgery; however, the methodological quality and clinical readiness of these models are yet to be systematically evaluated. This systematic review assessed the quality, risk of bias, and predictive performance of AI/ML preoperative risk prediction models in plastic surgery using the PROBAST+AI framework. Five databases were searched from inception through October 2025. Ten studies met the inclusion criteria, encompassing autologous breast reconstruction (n = 2), alloplastic breast reconstruction (n = 5), head and neck reconstruction (n = 1), burn surgery (n = 1), and aesthetic surgery (n = 1).
2. Biosynthesis of isoprene glycol from glucose by metabolically engineered Escherichia coli.
The researchers engineered Escherichia coli to synthesize isoprene glycol de novo from glucose, replacing a conventional petrochemical route. Optimization of the carboxylic acid reductase pathway, enzyme bioprospecting, and intracellular CoA availability increased production to 2.2 g/L with a yield of 0.11 g/g glucose.
Impact: This study establishes a proof of concept for renewable microbial production of a commercially relevant cosmetic humectant. It links metabolic engineering with sustainability by converting an inexpensive renewable carbon source into a non-petrochemical ingredient.
Clinical Implications: There is no immediate direct change to patient care. If the process achieves industrial-scale productivity, product consistency, safety qualification, and favorable life-cycle performance, it could support more sustainable sourcing of cosmetic and potentially dermatological formulation ingredients.
Key Findings
- Metabolically engineered Escherichia coli produced isoprene glycol de novo from glucose.
- The carboxylic acid reductase-mediated reduction route generated higher isoprene glycol levels than the alternative reduction strategy.
- Enzyme bioprospecting and increased intracellular CoA availability enabled a titer of 2.2 g/L and a yield of 0.11 g isoprene glycol/g glucose.
Methodological Strengths
- The study combined pathway engineering, comparison of two reduction strategies, enzyme bioprospecting, and cofactor-availability engineering.
- Production was demonstrated from glucose through a de novo biosynthetic route rather than by simply optimizing chemical conversion of an existing intermediate.
Limitations
- The abstract does not report fermentation scale-up data, productivity over time, or detailed process economics.
- The abstract does not establish industrial comparability, full life-cycle environmental benefits, or the safety and regulatory qualification of the biologically produced ingredient.
Future Directions: Further work should improve volumetric productivity and yield, evaluate fed-batch and continuous fermentation, characterize downstream purification and product quality, compare life-cycle impacts with petrochemical production, and establish toxicological and regulatory profiles for cosmetic use.
Isoprene glycol (ISPG) is a valuable humectant used in the cosmetic industry. However, its current commercial production relies on conventional petrochemical processes, which are energy-consuming and non-sustainable. To establish a green alternative, we engineered Escherichia coli to produce ISPG de novo from glucose. This engineered E. coli converts central metabolite acetyl-CoA to a non-natural metabolite 3-hydroxy-3-methylbutyryl-CoA (HMB-CoA). Subsequently, two different reduction strategies were used to reduce HMB-CoA to ISPG. Carboxylic acid reductase (CAR)-mediated reduction route resulted in higher levels of ISPG produced. Through subsequent enzyme bio-prospecting and increasing intracellular CoA availability, the resulting strain produced an ISPG titer of 2.2 g/L with a yield of 0.11 g ISPG/g glucose.